One of the common effects of lithium (Li) and valproic acid (VPA) is their ability to protect against excitotoxic insults. Neurodegenerative and neuropsychiatric diseases may be also associated with altered trophic support of brain-derived neurotrophic factor (BDNF), the most widely distributed neurotrophin in the central nervous system. However, despite these evidences, the effect of Li–VPA combination on BDNF after excitoxic insult has been inadequately investigated. We address this issue by exposing a human neuroblastoma cell line (SH-SY5Y) to neurotoxic concentration of L-glutamate and exploring whether the neuroprotective action of Li–VPA on these cells is associated with changes in BDNF protein and mRNA levels. The results showed that pre-incubation of Li–VPA abolished the toxic effect of glutamate on SH-SY5Y cell survival and this neuroprotective effect was associated with increased synthesis and mRNA expression of BDNF after 24 and 48 h of incubation. In conclusion, this study demonstrates that the neuroprotective effects of Li-VPA against glutamate-induced neurotoxicity in SH-SY5Y neuroblastoma cells is associated with increased synthesis and mRNA expression of BDNF. These data further support the idea that these two drugs can be used for prevention and/or treatment of glutamate-related neurodegenerative disorders.
AngelucciFAloeLJiménez-VasquezPMathéAA (2003) Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int J Neuropsychopharmacol6: 225–231.
AsaiTBundoMSugawaraH (2013) Effect of mood stabilizers on DNA methylation in human neuroblastoma cells. Int J Neuropsychopharmacol16: 2285–2294.
4.
BachmannRFSchloesserRJGouldTDManjiHK (2005) Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol32: 173–202.
5.
BalaratnasingamSJancaA (2012) Brain derived neurotrophic factor: a novel neurotrophin involved in psychiatric and neurological disorders. Pharmacol Ther134: 116–124.
6.
BaquetZCBickfordPCJonesKR (2005) Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci25: 6251–6259.
7.
BezchlibnykYBSunXWangJFMacQueenGMMcEwenBSYoungLT (2007) Neuron somal size is decreased in the lateral amygdalar nucleus of subjects with bipolar disorder. J Psychiatry Neurosci32: 203-210.
8.
CarvalhoALCaldeiraMVSantosSDDuarteCB (2008) Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br J Pharmacol153: S310–S324.
9.
CastroAAGhisoniKLatiniAQuevedoJTascaCIPredigerRD (2012) Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson’s disease. Behav Brain Res229: 208–215.
10.
Cechinel-ReccoKValvassoriSSVarelaRB (2012) Lithium and tamoxifen modulate cellular plasticity cascades in animal model of mania. J Psychopharmacol26: 1594–1604.
11.
ChangKBarnea-GoralyNKarchemskiyA (2005) Cortical magnetic resonance imaging findings in familial pediatric bipolar disorder. Biol Psychiatry58: 197–203.
12.
ChiuCTLiuGLeedsPChuangDM (2011) Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington’s disease. Neuropsychopharmacology36: 2406–2421.
13.
ChiuCTWangZHunsbergerJGChuangDM (2013) Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev65: 105–142.
14.
ChuangDM (2004) Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?Crit Rev Neurobiol16: 83–90.
15.
ChuangDMManjiHK (2007) In search of the holy grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked?Biol Psychiatry62: 4–6.
16.
Cohen-CorySKidaneAHShirkeyNJMarshakS (2010) Brain-derived neurotrophic factor and the development of structural neuronal connectivity. Dev Neurobiol 70: 271–288.
17.
CousinsDAGrunzeH (2012) Interpreting magnetic resonance imaging findings in bipolar disorder. CNS Neurosci Ther18: 201–207.
18.
CroceNDinalloVRicciV (2011) Neuroprotective effect of neuropeptide Y against β-amyloid 25-35 toxicity in SH-SY5Y neuroblastoma cells is associated with increased neurotrophin production. Neurodegener Dis8: 300–309.
19.
CunhaABFreyBNAndreazzaAC (2006) Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett398: 215–219.
20.
de SousaRTvan de BiltMTDinizBS (2011) Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett494: 54–56.
21.
DiasVVBrissosSFreyBNAndreazzaACCardosoCKapczinskiF (2009) Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord11: 663–671.
22.
DrevetsWC (2001) Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol11: 240–249.
23.
EinatHYuanPGouldTD (2003) The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci23: 7311–7316.
24.
EkmanCJLindJRydenEIngvarMLandenM (2010) Manic episodes are associated with grey matter volume reduction – a voxel-based morphometry brain analysis. Acta Psychiatr Scand122: 507–515.
25.
EnciuAMNicolescuMIManoleCGMureşanuDFPopescuLMPopescuBO (2011) Neuroregeneration in neurodegenerative disorders. BMC Neurol11: 75.
26.
FemeníaTGómez-GalánMLindskogMMagaraS (2012) Dysfunctional hippocampal activity affects emotion and cognition in mood disorders. Brain Res1476: 58–70.
27.
FengHLLengYMaCHZhangJRenMChuangDM (2008) Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience155: 567–572.
28.
FischerASananbenesiFWangXDobbinMTsaiLH (2007) Recovery of learning and memory is associated with chromatin remodelling. Nature447: 178–182.
29.
ForlenzaOVde PaulaVJMachado-VieiraRDinizBSGattazWF (2012) Does lithium prevent Alzheimer’s disease?Drugs Aging29: 335–342.
30.
FreyBNAndreazzaACCeresérKM (2006) Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci79: 281–286.
31.
FreyBNZunta-SoaresGBCaetanoSC (2008) Illness duration and total brain gray matter in bipolar disorder: evidence for neurodegeneration?Eur Neuropsychopharmacol18: 717-722.
32.
FukumotoTMorinobuSOkamotoYKagayaAYamawakiS (2001) Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl)158: 100–106.
33.
Giménez-CassinaALimFDíaz-NidoJ (2012) Chronic inhibition of glycogen synthase kinase-3 protects against rotenone-induced cell death in human neuron-like cells by increasing BDNF secretion. Neurosci Lett531: 182–187.
HashimotoKShimizuEIyoM (2004) Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev45: 104–114.
36.
HashimotoRHoughCNakazawaTYamamotoTChuangDM (2002) Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem80: 589–597.
37.
HennionJPel-MasriMAHuffMOel-MailakhRS (2002) Evaluation of neuroprotection by lithium and valproic acid against ouabain-induced cell damage. Bipolar Disord4: 201–206.
38.
JakobssonJZetterbergHBlennowKJohan EkmanCJohanssonAGLandénM (2013) Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder. Neuropsychopharmacology38: 664–672.
39.
JornadaLKMorettiMValvassoriSS (2010) Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain. J Psychiatr Res44: 506–510.
40.
KaregeFPerretGBondolfiGSchwaldMBertschyGAubryJM (2002) Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res109: 143–148.
41.
KemptonMJGeddesJREttingerUWilliamsSCGrasbyPM (2008) Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry65: 1017–1032.
42.
KidaS (2012) A functional role for CREB as a positive regulator of memory formation and LTP. Exp Neurobiol21: 136–140.
43.
KonarskiJZMcIntyreRSKennedySHRafi-TariSSoczynskaJKKetterTA (2008) Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord10: 1–37.
44.
LauterbachEC (2013) Neuroprotective effects of psychotropic drugs in Huntington’s disease. Int J Mol Sci14: 22558-22603.
45.
LauterbachECFontenelleLFTeixeiraAL (2012) The neuroprotective disease-modifying potential of psychotropics in Parkinson’s disease. Parkinsons Dis2012; 1–15.
46.
LengYChuangDM (2006) Endogenous-synuclein is potently induced by valproate and participates in the neuroprotection against glutamate excitotoxicity. J Neurosci26: 7502–7512.
47.
LengYLiangMHRenMMarinovaZLeedsPChuangDM (2008) Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci28: 2576–2588.
48.
LenoxRHWangL (2003) Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. Mol Psychiatry8: 135-144.
49.
LeyheTEschweilerGWStranskyE (2009) Increase of BDNF serum concentration in lithium treated patients with early Alzheimer’s disease. J Alzheimers Dis16: 649–656.
50.
LinDMokHYathamLN (2006) Polytherapy in bipolar disorder. CNS Drugs20: 29–42.
51.
LvLHanXSunYWangXDongQ (2012) Valproic acid improves locomotion in vivo after SCI and axonal growth of neurons in vitro. Exp Neurol233: 783–790.
52.
Machado-VieiraRDietrichMOLekeR (2007) Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry61: 142–144.
53.
Machado-VieiraRManjiHKZarateCA (2009) The role of lithium in the treatment of bipolar disorder: Convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord11: 92–109.
54.
ManjiHKDrevetsWCCharneyDS (2001) The cellular neurobiology of depression. Nat Med7: 541–547.
55.
ManjiHKQuirozJASpornJ (2003) Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry53: 707–742.
56.
MariniAMJiangXWuX (2004) Role of brain-derived neurotrophic factor and NF-kappaB in neuronal plasticity and survival: from genes to phenotype. Restor Neurol Neurosci22: 121–130.
57.
MoraAGonzález-PoloRAFuentesJMSolerGCentenoF (1999) Different mechanisms of protection against apoptosis by valproate and Li+. Eur J Biochem266: 886–891.
58.
MössnerRDanielSAlbertD (2000) Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem Int36: 197–202.
59.
MurerMGYanQRaisman-VozariR (2001) Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease. Prog Neurobiol63: 71–124.
60.
NagaharaAHTuszynskiMH (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov10: 209–219.
61.
NishinoSOhtomoKNumataYSatoTNakahataNKuritaM (2012) Divergent effects of lithium and sodium valproate on brain-derived neurotrophic factor (BDNF) production in human astrocytoma cells at therapeutic concentrations. Prog Neuropsychopharmacol Biol Psychiatry39: 17–22.
62.
NobleWPlanelEZehrC (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA102: 6990–6995.
63.
NonakaSHoughCJChuangDM (1998) Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA95: 2642–2647.
64.
OmataNMurataTTakamatsuS (2008) Neuroprotective effect of chronic lithium treatment against hypoxia in specific brain regions with upregulation of cAMP response element binding protein and brain-derived neurotrophic factor but not nerve growth factor: comparison with acute lithium treatment. Bipolar Disord10: 360–368.
65.
PålhagenSQiHMårtenssonBWålinderJGranérusAKSvenningssonP (2010) Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson’s disease and major depression. J Neurol257: 524-532.
66.
PhielCJWilsonCALeeVMKleinPS (2003) GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature423: 435–439.
67.
PostRM (2007) Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res41: 979-990.
68.
ProfennoLAJakimovichLHoltCJPorsteinssonATariotPN (2005) A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer’s disease. Curr Alzheimer Res2: 553–558.
RajkowskaG (2002) Cell pathology in bipolar disorder. Bipolar Disord4: 105-116.
71.
RockensteinETorranceMAdameA (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer’s disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci27: 1981–1991.
72.
RybakowskiJKSuwalskaA (2010) Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol13: 617–622.
73.
SchinderAFPooM (2000) The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci23: 639–645.
74.
ShaltielGChenGManjiHK (2007) Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol7: 22–26.
75.
ShimizuEHashimotoKOkamuraN (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry54: 70–75.
76.
SolomonDAKeitnerGIRyanCEMillerIW (1998) Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder. J Clin Psychopharmacol18: 38–49.
77.
StertzLFriesGRAguiarBW (2013) Histone deacetylase activity and brain-derived neurotrophic factor (BDNF) levels in a pharmacological model of mania. Rev Bras Psiquiatr10: 0–0 [Epub ahead of print].
78.
SuHZhangWGuoJGuoAYuanQWuW (2009) Lithium enhances the neuronal differentiation of neural progenitor cells in vitro and after transplantation into the avulsed ventral horn of adult rats through the secretion of brain-derived neurotrophic factor. J Neurochem108: 1385–1398.
79.
SuwalskaASobieskaMRybakowskiJK (2010) Serum brain-derived neurotrophic factor in euthymic bipolar patients on prophylactic lithium therapy. Neuropsychobiology62: 229–234.
80.
TarditoDPerezJTiraboschiEMusazziLRacagniGPopoliM (2006) Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev58: 115–134.
81.
TariotPNLoyRRyanJMPorsteinssonAIsmailS (2002) Mood stabilizers in Alzheimer’s disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev54: 1567–1577.
82.
TariotPNSchneiderLSCummingsJ (2011) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry68: 853–861.
83.
TwissJLChangJHSchanenNC (2006) Pathophysiological mechanisms for actions of the neurotrophins. Brain Pathol16: 320–332.
84.
VecseyCGHawkJDLattalKM (2007) Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB: CBP-dependent transcriptional activation. J Neurosci27: 6128–6140.
85.
VecslerMSimonAJAmariglioNRechaviGGakE (2010) MeCP2 deficiency downregulates specific nuclear proteins that could be partially recovered by valproic acid in vitro. Epigenetics5: 61–67.
86.
WangZFFesslerEBChuangDM (2011) Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. Acta Pharmacol Sin32: 1433–1445.
87.
WilotLCBernardiAFrozzaRL (2007) Lithium and valproate protect hippocampal slices against ATP-induced cell death. Neurochem Res32: 1539–1546.
88.
YasudaSLiangMHMarinovaZYahyaviAChuangDM (2009) The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry14: 51–59.
89.
YuFWangZTanakaM (2013) Posttrauma cotreatment with lithium and valproate: reduction of lesion volume, attenuation of blood-brain barrier disruption, and improvement in motor coordination in mice with traumatic brain injury. J Neurosurg119: 766–773.
90.
YucelKTaylorVHMcKinnonMC (2008) Bilateral hippocampal volume increase in patients with bipolar disorder and short-term lithium treatment. Neuropsychopharmacology33: 361–367.
91.
ZarateCADuJQuirozJ (2003) Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann NY Acad Sci1003: 273–291.
92.
ZhangXHengXLiT (2011) Long-term treatment with lithium alleviates memory deficits and reduces amyloid-β production in an aged Alzheimer’s disease transgenic mouse model. J Alzheimers Dis24:739–749.
